Endobronchial Ultrasound Biopsy Device Market Size - Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2025 - 2034

Endobronchial Ultrasound Biopsy Device Market Size

The global endobronchial ultrasound biopsy device market garnered notable revenues in 2024 and is expected to grow at a notable CAGR during 2025-2034, driven by the rising prevalence of respiratory diseases, including lung cancer, and increasing demand for minimally invasive diagnostic technology in the medical industry. As stated by the Lung Cancer Research Foundation, the U.S. will have 226,650 lung cancer diagnoses by the end of 2025. 1 in 16 people will be diagnosed with lung cancer in their lifetime.
 

Endobronchial ultrasound (EBUS) biopsy devices offer a non-invasive method and an invaluable tool for the diagnosis, staging, and management of pulmonary disease patients/ lung cancer. Lung cancer is one of the most diagnosed cancers in the world and a leading cause of cancer-related deaths, with over 2 million newly diagnosed patients annually. With the rise of lung cancer diagnoses, we have seen an increasing number of patients exploring the use of advanced imaging diagnostic tools, particularly advanced imaging tools that can provide real-time imaging and tissue samples with reduced risk to the patient.
 

EBUS biopsy devices are emerging technologies that use ultrasound waves to visualize the airways and surrounding tissues, thereby allowing a physician to obtain biopsy specimens from challenging biopsy locations in the lungs. Overall, the demand for these devices will continue to grow. There is a growing need for effective diagnostic methods, such as EBUS, due to the rise of respiratory diseases and a world population that is aging. The early detection of lung cancer and other pulmonary conditions is one essential aspect contributing to the growing acceptance of EBUS biopsy devices in clinical practice.
 

Furthermore, both physicians and patients have an increasing interest in minimally invasive procedures, which has increased the demand for the use of EBUS biopsy devices. Using EBUS biopsy decreases reliance on or need for open surgery, effectively minimizes patient and physician recovery time, decreases patient complications, and has made the EBUS biopsy device a favorable option in diagnosing lung cancer. However, a few restraints may affect the emerging market. Due to the high price of endobronchial ultrasound biopsy devices and maintenance costs, acceptance of these devices may be limited in low- and middle-income countries.
 

Endobronchial Ultrasound Biopsy Device Market Trends

The endobronchial ultrasound biopsy device industry has several emerging trends that will define its future growth. The trend toward hybrid systems that integrate EBUS with other imaging modalities such as computed tomography (CT) continues to generate interest. These systems offer improved visualization and greater accuracy in diagnosing and staging lung disease. Integrating different imaging techniques into one imaging system continues to improve the precision of biopsy procedures and ultimately patient outcomes.
 

The trend toward ultrasound-guided procedures continues to be recognized and adopted. Real-time imaging facilitates physicians making spur-of-the-moment adjustments during the biopsy procedure, enabling greater accuracy and greater safety during the biopsy. The increase of ultrasound-guided procedures will ultimately increase the pace and uptake of the EBUS biopsy device for use at the point of care, particularly in outpatient and specialty settings. The trend towards disposables for endobronchial ultrasound biopsy devices is increasing, with disposable biopsy needles and probes providing less risk of cross-contamination and improving patient safety. The growing emphasis on infection control and patient safety will further drive the trend towards disposables and single use for these devices.
 

Endobronchial Ultrasound Biopsy Device Market Analysis

Bronchoscopes and probes segment in endobronchial ultrasound biopsy device industry held sizeable growth in 2024. Ultrasound-enabled bronchoscope functionality allows physicians to visualize airways and adjacent structures, detect the presence of an abnormality, and direct a biopsy needle into the lesion. The addition of ultrasound to bronchoscopy to obtain tissue samples makes the process of sampling more accurate, which has made it possible to accurately diagnose lung cancer, tuberculosis, and other pulmonary disease processes. Bronchoscopes and probes are projected to take up a significant share of the EBUS market throughout the forecast period.
 

Newer advances in the technology of ultrasound are helping drive this growth, most notably higher-resolution ultrasound imaging and real-time guidance. The use of flexible bronchoscopes also has the potential to make minimally invasive procedures not only quicker but also reduce discomfort for the patient and recovery time and improve diagnostic and treatment accuracy. The demand for rigid bronchoscope and flexible bronchoscope will continue to be relevant because they are a pivotal tool that can be used for EBUS in countless situations/clinical environments.
 

Specialty centers in the endobronchial ultrasound biopsy device market generated significant revenues in 2024. Specialty centers typically conduct fewer invasive procedures as well as fewer diagnostics. These centers are the best fit for using biopsy devices for EBUS. This includes procedures involving lung cancer staging, diagnosis procedures, and biopsy procedures that are less risky and more accurate when conducted with EBUS devices. The increased precision of EBUS and lower risk have led to increased EBUS at specialty care centers. The growing demand for diagnostic innovations at specialty care centers has contributed to the increased preference for outpatient surgery and developments in lower-cost diagnostic options. Specialty care centers are typically better able to respond to the increasing number of patients diagnosed with early-stage lung cancer and gaining a larger share of what has been an existing market (pulmonary procedures) through EBUS in outpatient centers. North America (By Region)
 

North America endobronchial ultrasound biopsy device market held the largest share in 2024 and is expected to grow through 2034 driven by regional market aspects such as the high prevalence of lung cancer in North America, a well-developed healthcare infrastructure, and early adoption of advanced medical technologies, which allows for the use of EBUS biopsy devices. The market in the United States particularly shows continuous strength due to the high volume of diagnostic centers, hospitals, and specialty care clinics typically outfitted with advanced diagnostic tools. Additionally, the increasing awareness regarding the benefits of early detection of lung cancer, paired with the upward trend of healthcare providers utilizing minimally invasive procedures, will drive demand for EBUS biopsy devices in North America.
 

Endobronchial Ultrasound Biopsy Device Market Share

Some of the key companies in the endobronchial ultrasound biopsy device industry include:

• Veran Medical Technologies
• Clinodevice
• Medtronic Plc
• Olympus Corporation
• Conmed
• Boston Scientific Corporation
   

To enhance their market presence and positioning, companies operating in the endobronchial ultrasound biopsy device market are pursuing varied strategies. Our research indicates that key players are investing heavily in research and development to innovate and improve the functionality of their EBUS devices. As a result, many manufacturers are focusing on developing advanced systems that can perform imaging, offer real-time guidance, and support multiple imaging modalities. In addition to R&D investments, companies are also introducing disposable biopsy components to their product offerings, which improves patient safety and reduces the risk of cross-contamination. These products are being received extremely well, which reflects heightened concerns over infection control and patient safety.
 

Endobronchial Ultrasound Biopsy Device Industry News

• In September 2023, Broncus Medical introduced the BioStar Transbronchial Aspiration Needle (TBNA) for minimally invasive diagnostic applications. Medical professionals used the new needle to obtain precise tissue samples and high-quality specimens essential for diagnosing and staging lung cancer. The needle seamlessly integrated with endobronchial ultrasound bronchoscopy (EBUS) procedures, enhancing clinical outcomes and patient care.
   
• In September 2023, Galvanize Therapeutics treated the first patient in the AFFINITY clinical study. The trial aimed to assess the safety and technical success of the Aliya Pulsed Electric Field (PEF) System in patients with stage IV non-small cell lung cancer or lung metastases. Dr. Michael Pritchett, a pulmonology specialist at Pinehurst Medical Clinic, performed the procedure using the Aliya Endobronchial Needle through robotic-assisted bronchoscopy, marking its first use in the U.S.